Pipeline Programs↗
Active Trials↗
Companies Involved↗
Respiratory Distress Syndrome is an emerging landscape with 25 programs across 39 companies. 7 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
90%
Small molecule
19 of 21 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.
Analysis
225
clinical trials
Clinical Trials
225 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)